Minimal Residual Disease Test
Provided a roadmap for a molecular diagnostics company developing a new technology to detect minimal residual disease to secure Current Procedural Terminology (CPT) coding and positive Medicare coverage and reimbursement in the US.
Provided a roadmap for a molecular diagnostics company developing a new technology to detect minimal residual disease to secure Current Procedural Terminology (CPT) coding and positive Medicare coverage and reimbursement in the US.
CEO insights
Related articles
Real analysis from people who’ve been there
Remote Therapeutic Monitoring
ADVI worked with the client and the AMA’s Digital Medicine Payment Advisory Committee to develop new CPT codes for remote therapeutic monitoring.
Cardiovascular Technologies
Reviewed primary clinical study literature and, based on published Medicare precedents and processes, produced mock National Coverage Determinations on several invasive cardiovascular technologies, applying typical CMS standards and formats.
Lumbar Spine Stenosis Device
ADVI worked with the client and CMS to reverse a negative draft NCD and obtained a final NCD with CED that required a randomized clinical study.
Non-Opioid Device Pain Relief Product
Assessed the positioning of a client's non-opioid pain relief device versus competitive products, including drugs and other devices used to treat pain.
AI Device for Osteoporosis Assessment
ADVI helped a client obtain a new Category I CPT code for the trabecular bone score AI software device.
Osseochondral Knee Implant
ADVI analyzed the reimbursement environment for a novel osseochondral implant under development to determine whether existing codes and payment would be sufficient for the new device.
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.